Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RARE Stock Forecast 2026-2027
$25.38
Current Price
$2.40B
Market Cap
Buy 17
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to RARE Price Targets
+278.3%
To High Target of $96.00
+89.1%
To Median Target of $48.00
-1.5%
To Low Target of $25.00
RARE Price Momentum
+11.4%
1 Week Change
+1.5%
1 Month Change
-31.6%
1 Year Change
+10.3%
Year-to-Date Change
-40.1%
From 52W High of $42.37
+38.8%
From 52W Low of $18.29
📊 TOP ANALYST CALLS
Did RARE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Ultragenyx is one of their latest high-conviction picks.
Latest RARE Stock Price Targets & Analyst Predictions
Based on our analysis of 25 Wall Street analysts, RARE has a bullish consensus with a median price target of $48.00 (ranging from $25.00 to $96.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $25.38, the median forecast implies a 89.1% upside. This outlook is supported by 17 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Kristen Kluska at Cantor Fitzgerald, projecting a 278.3% upside. Conversely, the most conservative target is provided by Salveen Richter at Goldman Sachs, suggesting a 1.5% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RARE Analyst Ratings
17
Buy
2
Hold
0
Sell
RARE Price Target Range
Low
$25.00
Average
$48.00
High
$96.00
Current: $25.38
Latest RARE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RARE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 21, 2026 | Cantor Fitzgerald | Kristen Kluska | Overweight | Maintains | $96.00 |
| May 8, 2026 | Wedbush | Laura Chico | Neutral | Maintains | $26.00 |
| May 8, 2026 | Guggenheim | Debjit Chattopadhyay | Buy | Maintains | $43.00 |
| May 6, 2026 | Wells Fargo | Benjamin Burnett | Overweight | Maintains | $47.00 |
| May 6, 2026 | Wedbush | Laura Chico | Neutral | Maintains | $26.00 |
| Apr 29, 2026 | Barclays | Eliana Merle | Overweight | Maintains | $43.00 |
| Apr 16, 2026 | Morgan Stanley | Jeffrey Hung | Overweight | Maintains | $67.00 |
| Mar 24, 2026 | Goldman Sachs | Salveen Richter | Neutral | Downgrade | $25.00 |
| Mar 12, 2026 | JP Morgan | Anupam Rama | Overweight | Maintains | $74.00 |
| Feb 18, 2026 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $79.00 |
| Feb 18, 2026 | Evercore ISI Group | Liisa Bayko | Outperform | Maintains | $34.00 |
| Feb 17, 2026 | Evercore ISI Group | Liisa Bayko | Outperform | Maintains | $37.00 |
| Feb 17, 2026 | Wedbush | Laura Chico | Neutral | Reiterates | $25.00 |
| Feb 17, 2026 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $50.00 |
| Feb 3, 2026 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $60.00 |
| Jan 5, 2026 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $60.00 |
| Jan 5, 2026 | Guggenheim | Debjit Chattopadhyay | Buy | Maintains | $52.00 |
| Jan 2, 2026 | B of A Securities | Tazeen Ahmad | Buy | Maintains | $58.00 |
| Dec 30, 2025 | Leerink Partners | Joseph Schwartz | Outperform | Maintains | $70.00 |
| Dec 30, 2025 | Baird | Joel Beatty | Outperform | Maintains | $47.00 |
Ultragenyx Pharmaceutical Inc. (RARE) Competitors
The following stocks are similar to Ultragenyx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ultragenyx Pharmaceutical Inc. (RARE) Financial Data
Ultragenyx Pharmaceutical Inc. has a market capitalization of $2.40B with a P/E ratio of -4.3x. The company generates $670.00M in trailing twelve-month revenue with a -90.9% profit margin.
Revenue growth is -2.2% quarter-over-quarter, while maintaining an operating margin of -102.2% and return on equity of +787.7%.
Valuation Metrics
Market Cap
$2.40B
Enterprise Value
$3.18B
P/E Ratio
-4.3x
PEG Ratio
-0.2x
Price/Sales
3.7x
Growth & Margins
Revenue Growth (YoY)
-2.2%
Gross Margin
+77.9%
Operating Margin
-102.2%
Net Margin
-90.9%
EPS Growth
-2.4%
Financial Health
Cash/Price Ratio
+16.6%
Current Ratio
2.0x
Debt/Equity
-5.2x
ROE
+787.7%
ROA
-25.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Ultragenyx Pharmaceutical Inc. (RARE) Business Model
About Ultragenyx Pharmaceutical Inc.
What They Do
Develops therapies for rare genetic diseases.
Business Model
The company identifies unmet medical needs in rare diseases and develops specialized treatments. It generates revenue by marketing its approved therapies for conditions like X-linked hypophosphatemia and mucopolysaccharidosis VII, while also advancing a diverse pipeline of potential drug candidates targeting various genetic disorders.
Additional Information
Founded in 2010 and headquartered in Novato, California, Ultragenyx plays a significant role in the biopharmaceutical market for rare diseases, utilizing multiple drug modalities including biologics and small molecules to address serious health conditions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
1,294
CEO
Dr. Emil D. Kakkis M.D., Ph.D.
Country
United States
IPO Year
2014
Website
www.ultragenyx.comUltragenyx Pharmaceutical Inc. (RARE) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 04, 2026
By Zacks Equity Research
Realtime BLOG
Latest News
Quick Summary
Ultragenyx Pharmaceutical Inc. (RARE) presented at the Goldman Sachs 47th Annual Global Healthcare Conference, highlighting its strategic initiatives and developments in the healthcare sector.
Why It Matters
Ultragenyx's presentation at a major healthcare conference signals potential advancements in its pipeline, which could influence stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Kuehn Law is investigating Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) for possible fiduciary duty breaches by executives regarding misrepresentations of setrusumab's efficacy and risks.
Why It Matters
The investigation into Ultragenyx Pharmaceutical's leadership could lead to legal repercussions and impact stock performance, as misrepresentations may erode investor confidence and affect future earnings.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Ultragenyx Pharmaceutical (NASDAQ: RARE) CEO Emil Kakkis will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 9, 2026, at 4 PM ET.
Why It Matters
Ultragenyx's CEO participation in a major healthcare conference signals potential insights into the company's strategy and growth, impacting investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Ultragenyx (RARE) reported earnings 30 days ago; investors should monitor upcoming developments and market reactions for potential stock movement.
Why It Matters
Ultragenyx's recent earnings report can indicate financial health and growth potential, influencing investor sentiment and stock performance moving forward.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Ultragenyx Pharmaceutical granted 17,567 restricted stock units to 11 new non-executive officers as part of its Employment Inducement Plan, effective May 16, 2026.
Why It Matters
The grant of restricted stock units to new non-executive officers indicates Ultragenyx's commitment to attracting talent, potentially enhancing its innovation and growth, which can positively impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Ultragenyx Pharmaceutical Inc. (RARE) presented at the Bank of America Global Healthcare Conference, sharing insights and updates relevant to investors.
Why It Matters
Ultragenyx's presentation at a major healthcare conference may indicate business updates, strategic direction, or potential partnerships, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About RARE Stock
What is Ultragenyx Pharmaceutical Inc.'s (RARE) stock forecast for 2026?
Based on our analysis of 25 Wall Street analysts, Ultragenyx Pharmaceutical Inc. (RARE) has a median price target of $48.00. The highest price target is $96.00 and the lowest is $25.00.
Is RARE stock a good investment in 2026?
According to current analyst ratings, RARE has 17 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $25.38. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RARE stock?
Wall Street analysts predict RARE stock could reach $48.00 in the next 12 months. This represents a 89.1% increase from the current price of $25.38. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ultragenyx Pharmaceutical Inc.'s business model?
The company identifies unmet medical needs in rare diseases and develops specialized treatments. It generates revenue by marketing its approved therapies for conditions like X-linked hypophosphatemia and mucopolysaccharidosis VII, while also advancing a diverse pipeline of potential drug candidates targeting various genetic disorders.
What is the highest forecasted price for RARE Ultragenyx Pharmaceutical Inc.?
The highest price target for RARE is $96.00 from Kristen Kluska at Cantor Fitzgerald, which represents a 278.3% increase from the current price of $25.38.
What is the lowest forecasted price for RARE Ultragenyx Pharmaceutical Inc.?
The lowest price target for RARE is $25.00 from Salveen Richter at Goldman Sachs, which represents a -1.5% decrease from the current price of $25.38.
What is the overall RARE consensus from analysts for Ultragenyx Pharmaceutical Inc.?
The overall analyst consensus for RARE is bullish. Out of 25 Wall Street analysts, 17 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $48.00.
How accurate are RARE stock price projections?
Stock price projections, including those for Ultragenyx Pharmaceutical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 3:40 AM UTC